Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

NCT00886769 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

84

Enrollment

INDUSTRY

Sponsor class

Stopped recommendation by Data Monitoring Committee

Conditions

Systemic Juvenile Idiopathic Arthritis

Interventions

DRUG: Canakinumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]
[object Object]